Philippe Backeljauw
Pediatric Endocrinology · Cincinnati, OHNPI 1770511883
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Biomarin Pharmaceutical Inc. at 38.8% of the total. 2025 is the largest year on record at $180,492, 6.7 times the $26,861 reported in 2019. Among pediatric endocrinology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 617 payments — averaging $1025.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$245K
- Ascendis Pharma Endocrinology Inc$174K
- Novo Nordisk Health Care AG$98K
- Novo Nordisk$30K
- Tolmar Pharmaceuticals, Inc.$23K
- Eton Pharmaceuticals, Inc.$18K
- plus $43K from 13 others
Across 312 payments — averaging $7715.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$1.5M
- Ipsen Biopharmaceuticals, Inc$848K
- Novo Nordisk AS$92K
What the payments were for
- Consulting fees$168,27627%
- Speaking & faculty fees$318,30650%
- Travel & lodging$135,15521%
- Food & beverage$10,4052%
- Education$2840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 249 | $245,196 |
| Ascendis Pharma Endocrinology Inc | 232 | $174,157 |
| Novo Nordisk Health Care AG | 55 | $97,846 |
| Novo Nordisk | 32 | $30,378 |
| Tolmar Pharmaceuticals, Inc. | 11 | $23,353 |
| Eton Pharmaceuticals, Inc. | 1 | $18,155 |
| Ipsen Biopharmaceuticals, Inc | 5 | $11,710 |
| Endo Pharmaceuticals Inc. | 8 | $5,967 |
| Tolmar, Inc. | 7 | $5,928 |
| Upsher-smith Laboratories LLC | 2 | $4,675 |
| Pfizer | 3 | $4,522 |
| Ipsen Innovation | 1 | $3,010 |
| AbbVie | 1 | $1,688 |
| Vistapharm, Inc. | 1 | $1,540 |
| Sandoz | 4 | $1,512 |
| Theratechnologies Inc. | 2 | $1,500 |
| Ipsen Biopharm Limited | 1 | $1,155 |
| Ultragenyx Pharmaceutical Inc. | 1 | $122 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SKYTROFA$170,272
- VOXZOGO 1.2mg$165,201
- Norditropin$71,596
- FENSOLVI$29,174
- INCRELEX$28,390
- Sogroya$18,890
- Alkindi$18,155
- KHINDIVI$18,155
- VOXZOGO$10,639
- SUPPRELIN$5,725
- NGENLA$3,322
- Lupron Depot$1,688
- Thyquidity$1,540
- OMNITROPE$1,512
- CRYSVITA$122
How this compares
$632,427 in reported general payments places this provider in the 95th percentile of 76 pediatric endocrinology providers in Ohio.
Other pediatric endocrinology in Cincinnati
- Andrew DauberCincinnati$192K
- Nana Hawa Yayah JonesCincinnati$92K
- Susan RoseCincinnati$17K
- Iris Gutmark-LittleCincinnati$14K
- Halley WassermanCincinnati$9K
- Amy ShahCincinnati$8K
- Ryan BradyCincinnati$5K
- Nicole SheanonCincinnati$3K
- Deborah ElderCincinnati$2K
- David KleinCincinnati$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.